Copyright © 1999 by the European Society of Cardiology.
Editorial
Editorials
How to use natriuretic peptide levels for diagnosis and prognosis
1999, 1999
References
- Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for ACE inhibition after myocardial infarction. Lancet. 1993;341:11091113[CrossRef][Web of Science][Medline]
- Pinamonti B, Di Leonarda A, Sinaga G, Camerini F. Restrictive LV filling pattern in dilated cardiomyopathy assessed by doppler echo: clinical, echocardiographic and haemodynamic correlation and prognostic implications. J Am Coll Cardiol. 1993;22:808815[Abstract]
- Fruhwald FM, Fahrleitner A, Watzinger N. Natriuretic peptides in patients with diastolic dysfunction due to idiopathic dilated cardiomyopathy. Eur Heart J. 1999;20:14151423
[Abstract/Free Full Text] - Yu CM, Sanderson JE, Sham IOL. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J. 1996;17:16941702
[Abstract/Free Full Text]
This article has been cited by other articles:
![]() |
M. Panteghini Role and importance of biochemical markers in clinical cardiology Eur. Heart J., July 2, 2004; 25(14): 1187 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R COWIE BNP: soon to become a routine measure in the care of patients with heart failure? Heart, June 1, 2000; 83(6): 617 - 618. [Full Text] |
||||
![]() |
S.P. Wright and R.N. Doughty Natriuretic peptides in the evaluation of suspected heart failure: studies in primary care are needed Eur. Heart J., April 1, 2000; 21(7): 594 - 594. [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

